{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:36:14Z","timestamp":1786703774441,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Finnish Institute for Health and Welfare"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Measles antibody levels decline after MMR vaccination, raising concerns about individual protection and maintenance of herd immunity. In Finland, MMR vaccinations started in 1982, and only sporadic measles cases have been observed since the late 1980s. This suggests that a high proportion of individuals are unlikely to transmit measles. We examine the sustainability of herd immunity by inferring the antibody threshold sufficient to interrupt measles transmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We utilized measles antibody data collected after the second MMR vaccine dose from 157 individuals in a Finnish MMR-vaccinated cohort at 8 sampling rounds during 1987\u20132012 (ages 6\u201331 years), with antibody concentrations measured using the haemagglutination inhibition assay and\/or enzyme immunoassay depending on the round. Antibody decline after vaccination was estimated and extrapolated beyond the study age range to predict the proportion exceeding candidate antibody thresholds in the 2022 Finnish population. Threshold sufficiency was evaluated by comparing this proportion with the critical proportion required to sustain the absence of measles epidemics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean follow-up time was over 20 years, with 68% of all potential samples available. After age 13, antibody levels declined slowly or very slowly, with first and second half-lives of 10 and 20, or 22 and 67 years, respectively. No unique threshold was identified. However, the continued absence of measles epidemics suggests a very slow decline and\/or a low (&lt;\u2009120 mIU\/ml) antibody threshold to interrupt transmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vaccine-induced protection against measles transmission appears long-lasting. For herd immunity, declining vaccine uptake poses a greater risk than waning immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02832-9","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:48:12Z","timestamp":1779878892000},"page":"2053-2063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population"],"prefix":"10.1007","volume":"54","author":[{"given":"Miracle","family":"Amadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5677-721X","authenticated-orcid":false,"given":"Simopekka","family":"V\u00e4nsk\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irja","family":"Davidkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Haario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuija","family":"Leino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merit","family":"Melin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Auranen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Kontio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"2832_CR1","first-page":"270","volume":"3R","author":"PL Panum","year":"1847","unstructured":"Panum PPL. Lagttagelser, anstillede under Meslinge-Epidemien paa Feroerne i Aaret 1846 [Observations made during the epidemic of measles on the Faroe Islands in the year 1846]. Bibliotf Laeger. 1847;3R:270\u2013344.","journal-title":"Bibliotf Laeger"},{"key":"2832_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/v8100282","volume":"8","author":"D Griffin","year":"2016","unstructured":"Griffin D. The immune response in measles: virus control, clearance and protective immunity. Viruses. 2016;8:282. https:\/\/doi.org\/10.3390\/v8100282.","journal-title":"Viruses"},{"key":"2832_CR3","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med Mass Med Soc. 2007;357:1903\u201315. https:\/\/doi.org\/10.1056\/NEJMoa066092.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"2832_CR4","doi-asserted-by":"publisher","first-page":"2400684","DOI":"10.2807\/1560-7917.ES.2025.30.16.2400684","volume":"30","author":"DN Springer","year":"2025","unstructured":"Springer DN, Borsodi C, Camp V, Redlberger-Fritz J, Holzmann M, Kundi H. Seroprevalence against measles, Austria, stratified by birth years 1922 to 2024. Eurosurveillance. 2025;30:2400684. https:\/\/doi.org\/10.2807\/1560-7917.ES.2025.30.16.2400684.","journal-title":"Eurosurveillance"},{"key":"2832_CR5","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1016\/S1473-3099(17)30307-9","volume":"17","author":"FM Guerra","year":"2017","unstructured":"Guerra FM, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, et al. The basic reproduction number (R 0) of measles: a systematic review. Lancet Infect Dis. 2017;17:e420\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(17)30307-9.","journal-title":"Lancet Infect Dis"},{"key":"2832_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1017\/S095026880100601X","volume":"127","author":"J Wallinga","year":"2001","unstructured":"Wallinga J, L\u00e9vy-Bruhl D, Gay NJ, Wachmann CH. Estimation of measles reproduction ratios and prospects for elimination of measles by vaccination in some Western European countries. Epidemiol Infect. 2001;127:281\u201395. https:\/\/doi.org\/10.1017\/S095026880100601X.","journal-title":"Epidemiol Infect"},{"key":"2832_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.cmi.2017.01.003","volume":"23","author":"P O\u2019Connor","year":"2017","unstructured":"O\u2019Connor P, Jankovic D, Muscat M, Ben-Mamou M, Reef S, Papania M, et al. Measles and rubella elimination in the WHO Region for Europe: progress and challenges. Clin Microbiol Infect. 2017;23:504\u201310. https:\/\/doi.org\/10.1016\/j.cmi.2017.01.003.","journal-title":"Clin Microbiol Infect"},{"key":"2832_CR8","unstructured":"European Centre for Disease Prevention and Control. Measles: Annual Epidemiological Report for 2019 [Internet]. Stockholm: ECDC. 2020. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/measles-2019-aer.pdf. Accessed 14 Dec 2024."},{"key":"2832_CR9","unstructured":"European Centre for Disease Prevention and Control. Number of measles cases by month and notification rate per million population by country, EU\/EEA and the UK, December 2019\u2013 November 2020 [Internet]. 2021 [cited 2024 Dec 14]. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/number-measles-cases-month-and-notification-rate-million-population-country-26. Accessed 14 Dec 2024."},{"key":"2832_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/0272989X02239651","volume":"23","author":"M Brisson","year":"2003","unstructured":"Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Mak. 2003;23:76\u201382. https:\/\/doi.org\/10.1177\/0272989X02239651.","journal-title":"Med Decis Mak"},{"key":"2832_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.coviro.2020.05.009","volume":"40","author":"L Yang","year":"2020","unstructured":"Yang L, Grenfell BT, Mina MJ. Waning immunity and re-emergence of measles and mumps in the vaccine era. Curr Opin Virol. 2020;40:48\u201354. https:\/\/doi.org\/10.1016\/j.coviro.2020.05.009.","journal-title":"Curr Opin Virol"},{"key":"2832_CR12","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.3390\/v13101982","volume":"13","author":"N L\u00f3pez-Perea","year":"2021","unstructured":"L\u00f3pez-Perea N, Fern\u00e1ndez-Garc\u00eda A, Echevarr\u00eda JE, De Ory F, P\u00e9rez-Olmeda M, Masa-Calles J. Measles in vaccinated people: epidemiology and challenges in surveillance and diagnosis in the post-elimination phase. Spain, 2014\u20132020. Viruses. 2021;13:1982. https:\/\/doi.org\/10.3390\/v13101982.","journal-title":"Viruses"},{"key":"2832_CR13","doi-asserted-by":"publisher","unstructured":"Leung J, Munir NA, Mathis AD, Filardo TD, Rota PA, Sugerman DE, et al. The Effects of Vaccination Status and Age on Clinical Characteristics and Severity of Measles Cases in the United States in the Postelimination Era, 2001\u20132022. Clin Infect Dis. 2024;ciae470. https:\/\/doi.org\/10.1093\/cid\/ciae470.","DOI":"10.1093\/cid\/ciae470"},{"key":"2832_CR14","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0264-410X(98)00081-4","volume":"16","author":"I Davidkin","year":"1998","unstructured":"Davidkin I, Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine. 1998;16:2052\u20137. https:\/\/doi.org\/10.1016\/S0264-410X(98)00081-4.","journal-title":"Vaccine"},{"key":"2832_CR15","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1086\/528993","volume":"197","author":"I Davidkin","year":"2008","unstructured":"Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and Rubella antibodies in an MMR-vaccinated cohort: A 20\u2010year follow\u2010up. J Infect Dis. 2008;197:950\u20136. https:\/\/doi.org\/10.1086\/528993.","journal-title":"J Infect Dis"},{"key":"2832_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/oxfordjournals.aje.a115827","volume":"133","author":"M Paunio","year":"1991","unstructured":"Paunio M, Virtanen M, Peltola H, Cantell K, Paunio P, Valle M, et al. Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and Rubella prevention program in Finland. Am J Epidemiol. 1991;133:1152\u201360. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a115827.","journal-title":"Am J Epidemiol"},{"key":"2832_CR17","first-page":"739","volume":"62","author":"T Leino","year":"2007","unstructured":"Leino T, Koskenniemi E, Saranp\u00e4\u00e4 P-R, Str\u00f6mberg N, Kilpi T. The vaccination coverage continues top high [Rokotuskattavuus edelleen huippuluokkaa]. L\u00e4\u00e4k\u00e4rilehti. 2007;62:739\u201343.","journal-title":"L\u00e4\u00e4k\u00e4rilehti"},{"key":"2832_CR18","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJM199411243312101","volume":"331","author":"H Peltola","year":"1994","unstructured":"Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, et al. The elimination of indigenous measles, mumps, and Rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med. 1994;331:1397\u2013402. https:\/\/doi.org\/10.1056\/NEJM199411243312101.","journal-title":"N Engl J Med"},{"key":"2832_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/S0140-6736(05)65134-3","volume":"350","author":"H Peltola","year":"1997","unstructured":"Peltola H, Davidkin I, Valle M, Paunio M, Hovi T, Heinonen OP, et al. No measles in Finland. Lancet. 1997;350:1364\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(05)65134-3.","journal-title":"Lancet"},{"key":"2832_CR20","doi-asserted-by":"publisher","DOI":"10.2807\/ese.17.22.20184-en","author":"A Kantele","year":"2012","unstructured":"Kantele A, Valtonen K, Davidkin I, Martelius T, V\u00f5\u017eelevskaja N, Skogberg K, et al. Travellers returning with measles from Thailand to Finland, April 2012: infection control measures. Euro [Internet]. 2012. https:\/\/doi.org\/10.2807\/ese.17.22.20184-en. [cited 2024 Dec 14];17.","journal-title":"Euro [Internet]"},{"key":"2832_CR21","unstructured":"Finnish Institute for Health and Welfare. Measles cases in Finland [Internet]. 2025 [cited 2026 Apr 28]. https:\/\/thl.fi\/aiheet\/infektiotaudit-ja-rokotukset\/taudit-ja-torjunta\/taudit-ja-taudinaiheuttajat-a-o\/tuhkarokko\/tuhkarokon-esiintyvyys-suomessa. Accessed 28 Apr 2026."},{"key":"2832_CR22","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/infdis\/jiz380","volume":"221","author":"S Bolotin","year":"2020","unstructured":"Bolotin S, Hughes SL, Gul N, Khan S, Rota PA, Severini A, et al. What Is the evidence to support a correlate of protection for measles? a systematic review. J Infect Dis. 2020;221:1576\u201383. https:\/\/doi.org\/10.1093\/infdis\/jiz380.","journal-title":"J Infect Dis"},{"key":"2832_CR23","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/infdis\/162.5.1036","volume":"162","author":"RT Chen","year":"1990","unstructured":"Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, et al. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990;162:1036\u201342. https:\/\/doi.org\/10.1093\/infdis\/162.5.1036.","journal-title":"J Infect Dis"},{"key":"2832_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.vaccine.2007.10.046","volume":"26","author":"BJ Cohen","year":"2007","unstructured":"Cohen BJ, Audet S, Andrews N, Beeler J. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine. 2007;26:59\u201366. https:\/\/doi.org\/10.1016\/j.vaccine.2007.10.046.","journal-title":"Vaccine"},{"key":"2832_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/infdis\/jiac039","volume":"226","author":"S Bolotin","year":"2022","unstructured":"Bolotin S, Osman S, Hughes SL, Ariyarajah A, Tricco AC, Khan S, et al. In elimination settings, measles antibodies wane after vaccination but not after infection: a systematic review and meta-analysis. J Infect Dis. 2022;226:1127\u201339. https:\/\/doi.org\/10.1093\/infdis\/jiac039.","journal-title":"J Infect Dis"},{"key":"2832_CR26","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/infdis\/jiz381","volume":"221","author":"SA Plotkin","year":"2020","unstructured":"Plotkin SA. Is there a correlate of protection for measles vaccine? J Infect Dis. 2020;221:1571\u20132. https:\/\/doi.org\/10.1093\/infdis\/jiz381.","journal-title":"J Infect Dis"},{"key":"2832_CR27","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/infdis\/172.6.1591","volume":"172","author":"BJ Ward","year":"1995","unstructured":"Ward BJ, Boulianne N, Ratnam S, Guiot M-C, Couillard M, De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis. 1995;172:1591\u20135. https:\/\/doi.org\/10.1093\/infdis\/172.6.1591.","journal-title":"J Infect Dis"},{"key":"2832_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.humimm.2012.02.016","volume":"73","author":"RM Jacobson","year":"2012","unstructured":"Jacobson RM, Ovsyannikova IG, Vierkant RA, Pankratz VS, Poland GA. Independence of measles-specific humoral and cellular immune responses to vaccination. Hum Immunol. 2012;73:474\u20139. https:\/\/doi.org\/10.1016\/j.humimm.2012.02.016.","journal-title":"Hum Immunol"},{"key":"2832_CR29","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/cid\/ciy286","volume":"67","author":"JD Cherry","year":"2018","unstructured":"Cherry JD, Zahn M. Clinical characteristics of measles in previously vaccinated and unvaccinated patients in California. Clin Infect Dis. 2018;67:1315\u20139. https:\/\/doi.org\/10.1093\/cid\/ciy286.","journal-title":"Clin Infect Dis"},{"key":"2832_CR30","doi-asserted-by":"publisher","first-page":"S559","DOI":"10.1093\/infdis\/jir098","volume":"204","author":"JS Rota","year":"2011","unstructured":"Rota JS, Hickman CJ, Sowers SB, Rota PA, Mercader S, Bellini WJ. Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission. J Infect Dis. 2011;204:S559\u201363. https:\/\/doi.org\/10.1093\/infdis\/jir098.","journal-title":"J Infect Dis"},{"key":"2832_CR31","doi-asserted-by":"publisher","unstructured":"Van Den Hoek A, Sonder GJ, Scholing M, Gijselaar D, Van Binnendijk RS. Two cases of mild IgM-negative measles in previously vaccinated adults, the Netherlands, April and July 2011. Eurosurveillance [Internet]. 2011 [cited 2024 Dec 14];16. https:\/\/doi.org\/10.2807\/ese.16.48.20028-en","DOI":"10.2807\/ese.16.48.20028-en"},{"key":"2832_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1017\/S0950268899004173","volume":"125","author":"N Andrews","year":"2000","unstructured":"Andrews N, Pebody RG, Berbers G, Blondeau C, Crovari P, Davidkin I, et al. The European sero-epidemiology network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol Infect. 2000;125:127\u201343. https:\/\/doi.org\/10.1017\/S0950268899004173.","journal-title":"Epidemiol Infect"},{"key":"2832_CR33","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1080\/21645515.2020.1871296","volume":"17","author":"FP Bianchi","year":"2021","unstructured":"Bianchi FP, Mascipinto S, Stefanizzi P, De Nitto S, Germinario C, Tafuri S. Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study. Hum Vaccines Immunother. 2021;17:2078\u201384. https:\/\/doi.org\/10.1080\/21645515.2020.1871296.","journal-title":"Hum Vaccines Immunother"},{"key":"2832_CR34","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1016\/j.vaccine.2023.08.018","volume":"41","author":"L Franconeri","year":"2023","unstructured":"Franconeri L, Antona D, Cauchemez S, L\u00e9vy-Bruhl D, Paireau J. Two-dose measles vaccine effectiveness remains high over time: a French observational study, 2017\u20132019. Vaccine. 2023;41:5797\u2013804. https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.018.","journal-title":"Vaccine"},{"key":"2832_CR35","doi-asserted-by":"publisher","unstructured":"Bitzegeio J, Majowicz S, Matysiak-Klose D, Sagebiel D, Werber D. Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014\/15: evidence for waning immunity. Eurosurveillance [Internet]. 2019 [cited 2024 Dec 14];24. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.17.1800529.","DOI":"10.2807\/1560-7917.ES.2019.24.17.1800529"},{"key":"2832_CR36","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1007\/s15010-025-02630-9","volume":"53","author":"K Muhsen","year":"2025","unstructured":"Muhsen K, Choi YH, Walker J, Andrews N, McDonald HI, Brown K, et al. Sero-prevalence of measles and rubella immunoglobulin G serum antibody in individuals 1\u201330 years old in England in 2018: implications for subsequent outbreaks prediction. Infection. 2025;53:2809\u201320. https:\/\/doi.org\/10.1007\/s15010-025-02630-9.","journal-title":"Infection"},{"key":"2832_CR37","first-page":"417","volume":"68","author":"J Siennicka","year":"2014","unstructured":"Siennicka J, Cz\u0119\u015bcik A, Trzci\u0144ska A. The significance for epidemiological studies anti-measles antibody detection examined by enzyme immunoassay (EIA) and plaque reduction neutralization test (PRNT). Przegl Epidemiol. 2014;68:417\u2013529.","journal-title":"Przegl Epidemiol"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02832-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:10:37Z","timestamp":1786702237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02832-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2832"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02832-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM, KA, and MK are members of the National Immunization Technical Advisory Group. MA, SV, ID, HH, and TL declare no potential conflicts of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been conducted under varying legislative frameworks over the decades. It was last approved by the Hospital District of Helsinki and Uusimaa Ethics Committee of Epidemiology and Public Health in 2011 (340\/13\/03\/00\/2011). All vaccinees, or their parents, have given written consent before the samples were collected.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}